The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery

Anesthesia and Analgesia

Volumn 83, Issue 6, 1996, Pages 1193-1199

  D'Errico, Celia C ^a   Shayevitz, Jay R ^b   Martindale, Sarah J ^b   Mosca, Ralph S ^b   Bove, Edward L ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ;

ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OPEN HEART SURGERY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REOPERATION;

EID: 0029958434     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199612000-00011     Document Type: Article

References (25)

1. van Oeveren W, Jansen NJ, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 1987;44:640-5.
2. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987;2:1289-91.
3. Levy JH, Pifarre R, Schaff HV, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995;92:2236-44.
4. Cosgrove DM III. Aprotinin for coronary artery bypass grafting: effect on postoperative renal function [invited commentary]. Ann Thorac Surg 1995;59:136.
5. Murkin JM, Lux J, Shannon NA, et al. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg 1994;107:554-61.
6. Bidstrup BP. European experience with aprotinin. In: Lemmer JH, ed. Clinical Management Conference: guidelines for monitoring heparinized patients during aprotinin treatment. West Haven, CT: Miles, Inc., Pharmaceutical Division, 1994:8-10.
7. Boldt J, Knothe C, Zickmann B, et al. Aprotinin in pediatric cardiac operations: platelet function, blood loss, and use of homologous blood. Ann Thorac Surg 1993;55:1460-6.
8. Boldt J, Knothe C, Zickmann B, et al. Comparison of two aprotinin dosage regimens in pediatric patients having cardiac operations. Influence on platelet function and blood loss. J Thorac Cardiovasc Surg 1993;105:705-11.
9. Boldt J, Zickmann B, Schindler E, et al. Influence of aprotinin on the thrombomodulin/protein C system in pediatric cardiac operations. J Thorac Cardiovasc Surg 1994;107:1215-21.
10. Dietrich W, Mossinger H, Spannagl M, et al. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations. J Thorac Cardiovasc Surg 1993;105:712-20.
11. Herynkopf F, Lucchese F, Pereira E, et al. Aprotinin in children undergoing correction of congenital heart defects. A doubleblind pilot study. J Thorac Cardiovasc Surg 1994;108:517-21.
12. Elliott MJ, Allen A. Aprotinin in paediatric cardiac surgery. Perfusion 1990;5:73-6.
13. Hazan E, Pasaoglu I, Demircin M, Bozer AY. The effect of aprotinin (Trasylol) on postoperative bleeding in cyanotic congenital heart disease. Turk J Pediatr 1991;33:99-109.
14. Penkoske PA, Entwistle LM, Marchak BE, et al. Aprotinin in children undergoing repair of congenital heart defects. Ann Thorac Surg 1995;60:529-32.
15. Edmunds LH. Aprotinin use in pediatric cardiac operations [invited letter]. J Thorac Cardiovasc Surg 1993;105:757-60.
16. Hardy JF, Bélisle S. Natural and synthetic antifibrinolytics in adult cardiac surgery: efficacy, effectiveness and efficiency. Can J Anaesth 1994;41:1104-12.
17. Curran JW, Lawrence DN, Jaffe H, et al. Acquired immunodeficiency syndrome (AIDS) associated with transfusions. N Engl J Med 1984;310:69-75.
18. McCullough J. The nation's changing blood supply system. JAMA 1993;269:2239-45.
19. Lackritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995;333:1721-5.
20. Miller RD. Transfusion therapy. In: Miller RD, Cucchiara RF, Miller ED, et al., eds. Anesthesia. Vol 2. New York: Churchill Livingstone, 1994:1619-46.
21. Wachtfogel YT, Hack CE, Nuijens JH, et al. Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation. Am J Physiol 1995;268:H1352-7.
22. Nagaoka H, Yamada T, Hatano R, et al. Clinical significance of bradykinin liberation during cardiopulmonary bypass and its prevention by a kallikrein inhibitor. Jpn J Surg 1975;5:222-33.
23. Bohrer H, Bach A, Fleischer F, Lang J. Adverse haemodynamic effects of high-dose aprotinin in a paediatric cardiac surgical patient. Anaesthesia 1990;45:853-4.
24. Wuthrich B, Schmid P, Schmid ER, et al. IgE-mediated anaphylactic reaction to aprotinin during anaesthesia. Lancet 1992;340:173-4.
25. Ranucci M, Corno A, Pavesi M, et al. Renal effects of low dose aprotinin in pediatric cardiac surgery. Minerva Anestesiol 1994;60:361-6.